Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

SEM vs DBVT vs ENSG vs ALKS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SEM
Select Medical Holdings Corporation

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$2.04B
5Y Perf.+89.2%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-58.8%
ENSG
The Ensign Group, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$10.18B
5Y Perf.+298.7%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+116.4%

SEM vs DBVT vs ENSG vs ALKS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SEM logoSEM
DBVT logoDBVT
ENSG logoENSG
ALKS logoALKS
IndustryMedical - Care FacilitiesBiotechnologyMedical - Care FacilitiesBiotechnology
Market Cap$2.04B$1712.35T$10.18B$5.90B
Revenue (TTM)$5.52B$0.00$5.27B$1.56B
Net Income (TTM)$134M$-168M$363M$153M
Gross Margin10.6%15.2%65.4%
Operating Margin5.8%8.5%12.3%
Forward P/E13.1x23.2x24.8x
Total Debt$3.70B$22M$4.15B$70M
Cash & Equiv.$27M$194M$504M$1.12B

SEM vs DBVT vs ENSG vs ALKSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SEM
DBVT
ENSG
ALKS
StockMay 20May 26Return
Select Medical Hold… (SEM)100189.2+89.2%
DBV Technologies S.… (DBVT)10041.2-58.8%
The Ensign Group, I… (ENSG)100398.7+298.7%
Alkermes plc (ALKS)100216.4+116.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: SEM vs DBVT vs ENSG vs ALKS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ENSG leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Select Medical Holdings Corporation is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. DBVT and ALKS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
SEM
Select Medical Holdings Corporation
The Income Pick

SEM is the #2 pick in this set and the best alternative if income & stability is your priority.

  • Dividend streak 0 yrs, beta 0.46, yield 1.5%
  • Lower P/E (13.1x vs 24.8x)
  • 1.5% yield, vs ENSG's 0.1%, (2 stocks pay no dividend)
Best for: income & stability
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the clearest fit if your priority is momentum.

  • +110.4% vs SEM's +11.1%
Best for: momentum
ENSG
The Ensign Group, Inc.
The Growth Play

ENSG carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
  • 7.5% 10Y total return vs SEM's 158.5%
  • Lower volatility, beta 0.42, current ratio 1.42x
  • Beta 0.42, yield 0.1%, current ratio 1.42x
Best for: growth exposure and long-term compounding
ALKS
Alkermes plc
The Quality Compounder

ALKS is the clearest fit if your priority is quality.

  • 9.8% margin vs DBVT's 0.3%
Best for: quality
See the full category breakdown
CategoryWinnerWhy
GrowthENSG logoENSG18.7% revenue growth vs DBVT's -100.0%
ValueSEM logoSEMLower P/E (13.1x vs 24.8x)
Quality / MarginsALKS logoALKS9.8% margin vs DBVT's 0.3%
Stability / SafetyENSG logoENSGBeta 0.42 vs DBVT's 1.26
DividendsSEM logoSEM1.5% yield, vs ENSG's 0.1%, (2 stocks pay no dividend)
Momentum (1Y)DBVT logoDBVT+110.4% vs SEM's +11.1%
Efficiency (ROA)ENSG logoENSG6.8% ROA vs DBVT's -89.0%

SEM vs DBVT vs ENSG vs ALKS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SEMSelect Medical Holdings Corporation
FY 2025
Health Care, Patient Service, Non-Medicare
61.5%$3.4B
Health Care, Patient Service, Medicare
28.6%$1.6B
Service, Other
9.9%$538M
DBVTDBV Technologies S.A.

Segment breakdown not available.

ENSGThe Ensign Group, Inc.
FY 2025
Skilled Services Segment
97.4%$4.8B
Standard Bearer Segment
2.6%$127M
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M

SEM vs DBVT vs ENSG vs ALKS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

SEM and DBVT operate at a comparable scale, with $5.5B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to SEM's 2.4%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSEM logoSEMSelect Medical Ho…DBVT logoDBVTDBV Technologies …ENSG logoENSGThe Ensign Group,…ALKS logoALKSAlkermes plc
RevenueTrailing 12 months$5.5B$0$5.3B$1.6B
EBITDAEarnings before interest/tax$465M-$112M$558M$212M
Net IncomeAfter-tax profit$134M-$168M$363M$153M
Free Cash FlowCash after capex$117M-$151M$406M$392M
Gross MarginGross profit ÷ Revenue+10.6%+15.2%+65.4%
Operating MarginEBIT ÷ Revenue+5.8%+8.5%+12.3%
Net MarginNet income ÷ Revenue+2.4%+6.9%+9.8%
FCF MarginFCF ÷ Revenue+2.1%+7.7%+25.1%
Rev. Growth (YoY)Latest quarter vs prior year+5.0%+18.4%+28.2%
EPS Growth (YoY)Latest quarter vs prior year-18.2%+91.5%+21.9%-4.1%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

SEM leads this category, winning 4 of 6 comparable metrics.

At 13.9x trailing earnings, SEM trades at a 53% valuation discount to ENSG's 29.8x P/E. On an enterprise value basis, SEM's 12.0x EV/EBITDA is more attractive than ENSG's 25.7x.

MetricSEM logoSEMSelect Medical Ho…DBVT logoDBVTDBV Technologies …ENSG logoENSGThe Ensign Group,…ALKS logoALKSAlkermes plc
Market CapShares × price$2.0B$1712.35T$10.2B$5.9B
Enterprise ValueMkt cap + debt − cash$5.7B$1712.35T$13.8B$4.9B
Trailing P/EPrice ÷ TTM EPS13.93x-0.76x29.85x24.76x
Forward P/EPrice ÷ next-FY EPS est.13.06x23.19x
PEG RatioP/E ÷ EPS growth rate2.16x
EV / EBITDAEnterprise value multiple12.04x25.71x17.25x
Price / SalesMarket cap ÷ Revenue0.37x2.01x4.00x
Price / BookPrice ÷ Book value/share1.00x0.66x4.59x3.28x
Price / FCFMarket cap ÷ FCF5.33x27.46x12.28x
SEM leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 5 of 9 comparable metrics.

ENSG delivers a 16.6% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricSEM logoSEMSelect Medical Ho…DBVT logoDBVTDBV Technologies …ENSG logoENSGThe Ensign Group,…ALKS logoALKSAlkermes plc
ROE (TTM)Return on equity+6.6%-130.2%+16.6%+8.8%
ROA (TTM)Return on assets+2.3%-89.0%+6.8%+5.4%
ROICReturn on invested capital+4.8%+7.0%+18.9%
ROCEReturn on capital employed+7.0%-145.7%+10.2%+14.2%
Piotroski ScoreFundamental quality 0–95457
Debt / EquityFinancial leverage1.82x0.13x1.86x0.04x
Net DebtTotal debt minus cash$3.7B-$172M$3.7B-$1.0B
Cash & Equiv.Liquid assets$27M$194M$504M$1.1B
Total DebtShort + long-term debt$3.7B$22M$4.2B$70M
Interest CoverageEBIT ÷ Interest expense4.41x-189.82x88.33x32.30x
ALKS leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ENSG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ENSG five years ago would be worth $20,324 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs SEM's +11.1%. The 3-year compound annual growth rate (CAGR) favors ENSG at 23.6% vs SEM's 2.4% — a key indicator of consistent wealth creation.

MetricSEM logoSEMSelect Medical Ho…DBVT logoDBVTDBV Technologies …ENSG logoENSGThe Ensign Group,…ALKS logoALKSAlkermes plc
YTD ReturnYear-to-date+11.4%+4.9%+0.3%+25.3%
1-Year ReturnPast 12 months+11.1%+110.4%+27.5%+16.5%
3-Year ReturnCumulative with dividends+7.4%+19.7%+88.9%+14.5%
5-Year ReturnCumulative with dividends-11.1%-69.1%+103.2%+60.9%
10-Year ReturnCumulative with dividends+158.5%-87.0%+752.0%-11.0%
CAGR (3Y)Annualised 3-year return+2.4%+6.2%+23.6%+4.6%
ENSG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SEM and ENSG each lead in 1 of 2 comparable metrics.

ENSG is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEM currently trades 96.8% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSEM logoSEMSelect Medical Ho…DBVT logoDBVTDBV Technologies …ENSG logoENSGThe Ensign Group,…ALKS logoALKSAlkermes plc
Beta (5Y)Sensitivity to S&P 5000.46x1.26x0.42x1.06x
52-Week HighHighest price in past year$16.99$26.18$218.00$36.60
52-Week LowLowest price in past year$11.65$7.53$133.81$25.17
% of 52W HighCurrent price vs 52-week peak+96.8%+76.3%+80.0%+96.7%
RSI (14)Momentum oscillator 0–10060.948.123.360.2
Avg Volume (50D)Average daily shares traded2.1M252K358K2.3M
Evenly matched — SEM and ENSG each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — SEM and ENSG each lead in 1 of 2 comparable metrics.

Analyst consensus: SEM as "Hold", DBVT as "Buy", ENSG as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 9.5% for SEM (target: $18). For income investors, SEM offers the higher dividend yield at 1.55% vs ENSG's 0.14%.

MetricSEM logoSEMSelect Medical Ho…DBVT logoDBVTDBV Technologies …ENSG logoENSGThe Ensign Group,…ALKS logoALKSAlkermes plc
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuy
Price TargetConsensus 12-month target$18.00$46.33$222.33$44.00
# AnalystsCovering analysts13151328
Dividend YieldAnnual dividend ÷ price+1.5%+0.1%
Dividend StreakConsecutive years of raises00120
Dividend / ShareAnnual DPS$0.25$0.24
Buyback YieldShare repurchases ÷ mkt cap+4.9%0.0%+0.2%+0.5%
Evenly matched — SEM and ENSG each lead in 1 of 2 comparable metrics.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SEM leads in 1 (Valuation Metrics). 2 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

SEM vs DBVT vs ENSG vs ALKS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SEM or DBVT or ENSG or ALKS a better buy right now?

For growth investors, The Ensign Group, Inc.

(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Select Medical Holdings Corporation (SEM) offers the better valuation at 13. 9x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SEM or DBVT or ENSG or ALKS?

On trailing P/E, Select Medical Holdings Corporation (SEM) is the cheapest at 13.

9x versus The Ensign Group, Inc. at 29. 8x. On forward P/E, Select Medical Holdings Corporation is actually cheaper at 13. 1x.

03

Which is the better long-term investment — SEM or DBVT or ENSG or ALKS?

Over the past 5 years, The Ensign Group, Inc.

(ENSG) delivered a total return of +103. 2%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SEM or DBVT or ENSG or ALKS?

By beta (market sensitivity over 5 years), The Ensign Group, Inc.

(ENSG) is the lower-risk stock at 0. 42β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 198% more volatile than ENSG relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — SEM or DBVT or ENSG or ALKS?

By revenue growth (latest reported year), The Ensign Group, Inc.

(ENSG) is pulling ahead at 18. 7% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: The Ensign Group, Inc. grew EPS 14. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SEM or DBVT or ENSG or ALKS?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SEM or DBVT or ENSG or ALKS more undervalued right now?

On forward earnings alone, Select Medical Holdings Corporation (SEM) trades at 13.

1x forward P/E versus 23. 2x for The Ensign Group, Inc. — 10. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — SEM or DBVT or ENSG or ALKS?

In this comparison, SEM (1.

5% yield), ENSG (0. 1% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is SEM or DBVT or ENSG or ALKS better for a retirement portfolio?

For long-horizon retirement investors, Select Medical Holdings Corporation (SEM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

46), 1. 5% yield, +158. 5% 10Y return). Both have compounded well over 10 years (SEM: +158. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SEM and DBVT and ENSG and ALKS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SEM is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; ENSG is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock. SEM pays a dividend while DBVT, ENSG, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SEM

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.6%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ENSG

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Net Margin > 5%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.